AXIOS November 4, 2025
The Trump administration is closing in on a deal to allow Medicare coverage of weight loss drugs by Eli Lilly and Novo Nordisk in some cases, according to multiple reports.
Why it matters: A deal could significantly expand seniors’ access to popular weight loss drugs while drastically decreasing the estimated cost of that coverage.
- It also could lead to a broader impact on people’s access to these drugs, since Medicare often influences what private insurers choose to cover.
The arrangement would be possible under a deal with the companies that would decrease the price of Novo Nordisk’s Wegovy to $149 a month on the TrumpRX website for the lowest dose and Eli Lilly’s Zepbound to $299,...
Today's Sponsors
Today's Sponsor